Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C6ZX
|
|||
| Former ID |
DIB010981
|
|||
| Drug Name |
KW-3357
|
|||
| Synonyms |
Coagulation factor inhibitor (iv, blood clotting disorder), Kyowa; Recombinant antithrombin (iv, blooding clottingdisorder), Kyowa Hakko Kirin
Click to Show/Hide
|
|||
| Indication | Coagulation defect [ICD-11: 3B10.0] | Phase 3 | [1] | |
| Company |
Kyowa Hakko Kogyo Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Antithrombin-III (ATIII) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01384903) An Open-label Study of KW-3357. U.S. National Institutes of Health. | |||
| REF 2 | Company report (kyowa-kirin) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.